Evaluation of HER2, p53, bcl-2, topoisomerase II-α, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes
Open Access
- 1 May 2001
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 12 (5) , 615-620
- https://doi.org/10.1023/a:1011182524684
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2Annals of Oncology, 2000
- Amplification and Deletion of Topoisomerase IIα Associate with ErbB-2 Amplification and Affect Sensitivity to Topoisomerase II Inhibitor Doxorubicin in Breast CancerThe American Journal of Pathology, 2000
- erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast CancerJNCI Journal of the National Cancer Institute, 1998
- erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast CancerJNCI Journal of the National Cancer Institute, 1998
- bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.Journal of Clinical Oncology, 1997
- Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.Journal of Clinical Oncology, 1996
- Clonal heterogeneity in breast cancer: Karyotypic comparisons of multiple intra—and extra—tumorous samples from 3 patientsInternational Journal of Cancer, 1995
- Stability of HER-2/neu Expression Over Time and at Multiple Metastatic SitesJNCI Journal of the National Cancer Institute, 1993
- Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.Journal of Clinical Oncology, 1992
- Heterogeneity for Allelic Loss in Human Breast CancerJNCI Journal of the National Cancer Institute, 1992